These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 16794737

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J, Janda J, Wei J, Chapatte L, Colombetti S, Alves P, Ritter G, Ayyoub M, Valmori D, Chen W, Lévy F.
    Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
    [Abstract] [Full Text] [Related]

  • 3. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
    Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S.
    J Immunother; 2008 Jul; 31(9):849-57. PubMed ID: 18833002
    [Abstract] [Full Text] [Related]

  • 4. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
    Hasegawa K, Noguchi Y, Koizumi F, Uenaka A, Tanaka M, Shimono M, Nakamura H, Shiku H, Gnjatic S, Murphy R, Hiramatsu Y, Old LJ, Nakayama E.
    Clin Cancer Res; 2006 Mar 15; 12(6):1921-7. PubMed ID: 16551878
    [Abstract] [Full Text] [Related]

  • 5. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
    Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Ayyoub M, Valmori D.
    Clin Cancer Res; 2009 Jul 01; 15(13):4467-74. PubMed ID: 19531622
    [Abstract] [Full Text] [Related]

  • 6. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
    Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F, Fossati-Bellani F, Old LJ, Parmiani G, Castelli C.
    Cancer Res; 2003 Oct 15; 63(20):6948-55. PubMed ID: 14583496
    [Abstract] [Full Text] [Related]

  • 7. A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.
    Ayyoub M, Souleimanian NE, Godefroy E, Scotto L, Hesdorffer CS, Old LJ, Valmori D.
    Clin Immunol; 2006 Oct 15; 118(2-3):188-94. PubMed ID: 16368270
    [Abstract] [Full Text] [Related]

  • 8. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM.
    Cancer Res; 2002 Jan 01; 62(1):213-8. PubMed ID: 11782380
    [Abstract] [Full Text] [Related]

  • 9. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
    Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, Greten TF.
    Clin Cancer Res; 2004 Jul 01; 10(13):4332-41. PubMed ID: 15240519
    [Abstract] [Full Text] [Related]

  • 10. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G, Guillaume P, Luescher I, Bhardwaj N, Mears G, Old L, Valmori D, Ayyoub M.
    J Immunother; 2009 Jul 01; 32(2):161-8. PubMed ID: 19238015
    [Abstract] [Full Text] [Related]

  • 11. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
    Ebert LM, Liu YC, Clements CS, Robson NC, Jackson HM, Markby JL, Dimopoulos N, Tan BS, Luescher IF, Davis ID, Rossjohn J, Cebon J, Purcell AW, Chen W.
    Cancer Res; 2009 Feb 01; 69(3):1046-54. PubMed ID: 19176376
    [Abstract] [Full Text] [Related]

  • 12. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, Tan B, Maraskovsky E, Miloradovic L, Hopkins W, Pan L, Venhaus R, Hoffman EW, Chen W, Cebon J.
    Clin Cancer Res; 2009 Mar 15; 15(6):2166-73. PubMed ID: 19276262
    [Abstract] [Full Text] [Related]

  • 13. Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber.
    Slager EH, van der Minne CE, Goudsmit J, van Oers JM, Kostense S, Havenga MJ, Osanto S, Griffioen M.
    Cancer Gene Ther; 2004 Mar 15; 11(3):227-36. PubMed ID: 14726960
    [Abstract] [Full Text] [Related]

  • 14. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
    Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY, Tai TY, Cohen CJ, Old LJ, Pfreundschuh M, Reiter Y, Hoogenboom HR, Renner C.
    Eur J Immunol; 2004 Oct 15; 34(10):2919-29. PubMed ID: 15368308
    [Abstract] [Full Text] [Related]

  • 15. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells.
    Muraoka D, Kato T, Wang L, Maeda Y, Noguchi T, Harada N, Takeda K, Yagita H, Guillaume P, Luescher I, Old LJ, Shiku H, Nishikawa H.
    J Immunol; 2010 Sep 15; 185(6):3768-76. PubMed ID: 20733202
    [Abstract] [Full Text] [Related]

  • 16. Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals.
    Valmori D, Souleimanian NE, Hesdorffer CS, Old LJ, Ayyoub M.
    Clin Immunol; 2005 Nov 15; 117(2):161-7. PubMed ID: 16103015
    [Abstract] [Full Text] [Related]

  • 17. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.
    Jäger E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E, Ritter G, Jäger D, Panicali D, Hoffman E, Pan L, Oettgen H, Old LJ, Knuth A.
    Proc Natl Acad Sci U S A; 2006 Sep 26; 103(39):14453-8. PubMed ID: 16984998
    [Abstract] [Full Text] [Related]

  • 18. [NY-ESO-1 and cancer immunotherapy].
    Peng JR, Leng XS.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug 26; 30(4):371-7. PubMed ID: 18795604
    [Abstract] [Full Text] [Related]

  • 19. Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses.
    Valmori D, Souleimanian NE, Hesdorffer CS, Ritter G, Old LJ, Ayyoub M.
    Clin Immunol; 2005 Oct 26; 117(1):24-30. PubMed ID: 15994128
    [Abstract] [Full Text] [Related]

  • 20. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.
    Gnjatic S, Atanackovic D, Jäger E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, Knuth A, Old LJ.
    Proc Natl Acad Sci U S A; 2003 Jul 22; 100(15):8862-7. PubMed ID: 12853579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.